| Ytd | 22.22% | |
| 1y | 30.71% |
| Open | 48.13 | Prev Close | 48.54 | Low | 46.61 | High | 48.84 | Mkt Cap | 2.46B |
| Vol | 529.12K | Avg Vol | 886.70K | EPS | 0.21 | P/E | 230.24 | Forward P/E | 111.98 |
| Beta | 1.23 | Short Ratio | 4.52 | Inst. Own | 105.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-27 | 50-d Avg | 37.83 | 200-d Avg | 34.07 | 1yr Est | 49.56 |
Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and rai
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme
Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on
BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price targ
AtriCure is building a broader surgical platform across appendage management, ablation, and postoper
AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial
On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a
This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduc
Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on Aug
On July 31, 2026, AtriCure Inc (ATRC) shares fell 6.0% today, bringing the current price to $37.76.
RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high
UBS analyst Priya Sachdeva maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price targe
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the q
AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Est
AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the
AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from th
AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.18 per share which beat the analyst consens
AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 analy
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quar
[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The la
Investors need to pay close attention to ATRC stock based on the movements in the options market lat
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc
[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises
2026 Financial GuidanceFull year 2026 revenue is projected to be approximately $600 million to $610
AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.00 per share which beat the analyst consens
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers
UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price ta
Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and low
AtriCure (NASDAQ:ATRC) is looking for FY2026 Adj EPS of $0.09-$0.15 vs $(0.04) analyst estimate. Aff
AtriCure (NASDAQ:ATRC) affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.0
AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.06 per share which beat the analyst consens
2026 Financial GuidanceManagement projects 2026 revenue of approximately $600 million to $610 millio
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fi
JP Morgan analyst Lilia-Celine Lozada maintains AtriCure (NASDAQ:ATRC) with a Overweight and rais